- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Opinion
Video
Nonsteroidal Topical Treatments for Plaque Psoriasis
Author(s):
Expert dermatologists highlight the use of nonsteroidal topical therapies, roflumilast and tapinarof, for the management of plaque psoriasis.
This is a video synopsis of a discussion involving Mark Lebwohl, MD, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in Manhattan, New York, and Saakshi Khattri, MD, a board-certified dermatologist, rheumatologist, and internist at the same institution.
The panelists discuss the introduction of two new topical therapies, roflumilast and tapinarof, for plaque psoriasis. Dr. Khattri highlights the advantages of these non-steroid options, including once-daily application and reduced concerns about long-term steroid use and associated side effects. Roflumilast's approval for children aged six and older and its efficacy in intertriginous psoriasis are noted as significant advancements.
Both drugs demonstrate high tolerability, with minimal local reactions or irritations observed in clinical trials. The panelists compare the new therapies to previous options, emphasizing their breakthrough nature in providing effective and well-tolerated treatment for psoriasis patients. Access to these medications is facilitated at Mount Sinai, with efforts made to ensure patients receive the best available treatments, including assistance with insurance approvals and utilization of discount pharmacies to alleviate financial burdens.
Dr. Lebwohl and Dr. Khattri agree that the availability of these topical therapies has transformed their approach to psoriasis treatment, minimizing the need for appeal letters and providing cost-effective solutions for patients. They express satisfaction with the efficacy and accessibility of these new treatments, underscoring the positive impact on patient care and outcomes.
Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.
